Physician Assistant in Adel, IA Accepting Medicare
5 Physician Assistant nurses found. Showing 1 - 5
 Lisa Marie Kirkpatrick, P A C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1120 Greene St, Adel, IA 50003 Phone: 515-993-4656 Fax: 515-993-4532 |
 Christopher Baltzell, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 710 Common Pl Ste 700, Adel, IA 50003 Phone: 515-875-9760 Fax: 515-875-9761 |
Michael S Barger, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 309 S 7th St, Suite B, Adel, IA 50003 Phone: 515-993-1099 Fax: 515-993-1105 |
Mace Walker Boshart, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1120 Greene St, Adel, IA 50003 Phone: 515-993-4656 Fax: 515-993-4532 |
Rebekah Christiansen, Physician Assistant Medicare: Medicare Enrolled Practice Location: 710 Common Pl Ste 700, Adel, IA 50003 Phone: 515-875-9760 Fax: 515-875-9761 |
News Archive
Students, faculty members attend CSU Health Policy Conference held in Sacramento
The CSU educates thousands of public health professionals who work to improve the health of California's communities by promoting healthy lifestyles, preventing disease and removing environmental dangers.
Heat treatment may zap cancer cells
Scientists believe they have discovered a clue as to why so many men with testicular cancer survive against the odds.
Affymetrix announces availability of SensationPlus FFPE Amplification and 3' IVT Labeling Kit
Affymetrix, Inc. announced today the availability of SensationPlus FFPE Amplification and 3' IVT Labeling Kit (SensationPlus FFPE Reagent Kit), consisting of RNA amplification and labeling modules, to enable gene expression profiling of formalin-fixed, paraffin-embedded (FFPE) samples on GeneChip 3' IVT arrays and Almac XcelTM Array for disease clinical research and retrospective studies.
Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.
› Verified 7 days ago